These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 9591517

  • 1. Highlights of the North American and European experiences.
    Goetz CG.
    Neurology; 1998 May; 50(5 Suppl 5):S15-6. PubMed ID: 9591517
    [Abstract] [Full Text] [Related]

  • 2. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G.
    J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
    Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R, Perret JE.
    Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
    Adler CH, Singer C, O'Brien C, Hauser RA, Lew MF, Marek KL, Dorflinger E, Pedder S, Deptula D, Yoo K.
    Arch Neurol; 1998 Aug; 55(8):1089-95. PubMed ID: 9708959
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tolcapone: a novel approach to Parkinson's disease.
    Micek ST, Ernst ME.
    Am J Health Syst Pharm; 1999 Nov 01; 56(21):2195-205. PubMed ID: 10565698
    [Abstract] [Full Text] [Related]

  • 11. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M, Yokochi M, Kuno S, Hattori Y, Tsukamoto Y, Narabayashi H, Tohgi H, Mizuno Y, Kowa H, Yanagisawa N, Kanazawa I.
    J Neural Transm (Vienna); 1997 Nov 01; 104(2-3):229-36. PubMed ID: 9203084
    [Abstract] [Full Text] [Related]

  • 12. Tolcapone: COMT inhibition for the treatment of Parkinson's disease.
    Fahn S.
    Neurology; 1998 May 01; 50(5 Suppl 5):S1-2. PubMed ID: 9591515
    [No Abstract] [Full Text] [Related]

  • 13. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.
    Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S.
    Neurology; 1998 May 01; 50(5 Suppl 5):S54-9. PubMed ID: 9591523
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
    Sabaté M, Bosch A, Pedrós C, Figueras A.
    Ann Pharmacother; 1999 Nov 01; 33(11):1228-9. PubMed ID: 10573327
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M, Leinonen M, Poewe W.
    J Neural Transm (Vienna); 2015 Dec 01; 122(12):1709-14. PubMed ID: 26347184
    [Abstract] [Full Text] [Related]

  • 17. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
    Jorga KM, Nicholl DJ.
    Br J Clin Pharmacol; 1999 Sep 01; 48(3):449-52. PubMed ID: 10510160
    [Abstract] [Full Text] [Related]

  • 18. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
    Gasser UE, Jorga K, Crevoisier C, Hovens SE, van Giersbergen PL.
    Eur Neurol; 1999 Sep 01; 41(4):206-11. PubMed ID: 10343151
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B.
    Clin Neuropharmacol; 2010 May 01; 33(3):135-41. PubMed ID: 20216409
    [Abstract] [Full Text] [Related]

  • 20. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
    Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN.
    Neurology; 1993 Dec 01; 43(12):2685-8. PubMed ID: 8255478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.